about
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: How successfully treated? - A case report with review of literature.Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.Proteasome inhibitors in the treatment of multiple myelomaBlockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myelomaKidney disease associated with plasma cell dyscrasiasState-of-the-Art Management of Complications of Myeloma and Its Treatment.Lenalidomide: a synthetic compound with an evolving role in cancer management.Emerging drugs for Waldenström's macroglobulinemia.Decreasing incidence of AA amyloidosis in Spain.Kidney disease and multiple myeloma.Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature.Lenalidomide in multiple myeloma.Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.Primary effusion lymphoma: current perspectives.
P2860
Q34130459-9AA0B0EA-F7B9-4AA9-ADCD-04766E9BB007Q34436631-E6045892-E2FC-4F16-9BD5-70A2AC2108FBQ34548422-B61B3AA0-EE6A-4C63-B5BD-223F762360B3Q34611676-77E417B9-18A1-4151-BB7F-D285CEBC861AQ36110746-1FD77E85-82EA-4BB5-9F20-AFEBA7C105BDQ37750106-0198C430-D67D-475B-B6A3-D010553CC755Q37776662-1DB12A99-12BF-44F6-A580-688BFF433913Q37791617-70BC9127-47A9-4665-BFB3-D4F14ABB2B96Q37847176-8B7E3A81-8022-4ECC-AE7F-16B15F6D9760Q38107554-1B91D911-C3C1-403E-B6CF-E553F7F70AB2Q38122674-B5CF4581-24C8-4A2C-A420-BD3F8DC51C9FQ38194434-4C91CB9B-E9DA-4BDA-8AE6-B60D249E37D5Q43247044-3DE42928-7911-4E1B-9281-08E0AAC6466EQ44468671-AD917058-A890-4B61-8491-AA5E3FFCB8D2Q50916755-6C718286-78B6-43CE-A27A-3CB96B10FA31Q54710993-72BE918B-6CBF-4045-9055-BE0F4B91000AQ55518093-D1A64571-EC3E-484C-8AF9-283C6277B350
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of plasma cell dyscrasias with lenalidomide.
@en
Treatment of plasma cell dyscrasias with lenalidomide.
@nl
type
label
Treatment of plasma cell dyscrasias with lenalidomide.
@en
Treatment of plasma cell dyscrasias with lenalidomide.
@nl
prefLabel
Treatment of plasma cell dyscrasias with lenalidomide.
@en
Treatment of plasma cell dyscrasias with lenalidomide.
@nl
P2860
P50
P356
P1433
P1476
Treatment of plasma cell dyscrasias with lenalidomide.
@en
P2860
P2888
P304
P356
10.1038/LEU.2008.123
P577
2008-05-29T00:00:00Z
P5875
P6179
1051012908